Live Chat ×
Skip to main content

Non Transplant Treatment for MDS (myelodysplastic syndromes)

Recorded March 2016 Interview with Dr. Luca Malcovati and Dr. David Steensma
Questions answered include:

  1. What is the role of the drug eltrombopag and the drug romiplostim?
  2. Are these drugs approved by the FDA for MDS?
  3. What are somatic mutations?
  4. Is there emerging data that suggests that some somatic mutations can help predict which patients may potentially benefit from available treatments?
  5. What are the details regarding the drug luspatercept?
  6. There has not been a new medicine for MDS approved by the FDA/EMA in a number of years, will luspatercept be the next drug to be approved due to its success in patients?
  7. What are the available treatments for MDS without the deletion of 5q?